Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Scribe Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 18.93M shares outstanding
USScribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines.
The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Leadership
Brett T. Staahl
Co-Founder & VP of External Innovation
David F. Savage
Co-Founder & Scientific Advisor
George Manning
VP & Controller
Jennifer A. Doudna
Co-Founder & Scientific Advisor
Employees
89
Country
US
Sector
Healthcare
Website
scribetx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Aghazadeh Behzad | Director | Purchase | 7.9K | $144.3K | Jul 28, 2026 |
 Doudna Jennifer A | 10% Owner | Conversion of Derivative | 12.5K | -- | Jul 27, 2026 |
 GORDON CARL L | Director | Conversion of Derivative | 2.07M | -- | Jul 27, 2026 |
 AH Bio Fund II, L.P. | 10% Owner | Conversion of Derivative | 2.05M | -- | Jul 27, 2026 |
| AH Bio Fund II, L.P. | 10% Owner | Conversion of Derivative | 697.6K | -- | Jul 27, 2026 |
| AH Bio Fund II, L.P. | 10% Owner | Conversion of Derivative | 4.13M | -- | Jul 27, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
 ELI LILLY & Co 10% Owner | 1.1M | 5.6% | FORM 4 |
 Doudna Jennifer A 10% Owner | 603.5K | 3.2% | FORM 4 |
 Staahl Brett 10% Owner | 524.3K | 2.8% | FORM 4 |
 Oakes Benjamin L. President, CEO, Director | 506.6K | 2.7% | FORM 4 |
 Lucas Svetlana Chief Business Officer | 30.7K | 0.2% | FORM 4 |
TEMA ETFS LLC | 3.0K | 0.0% | 13F |
Sterling Capital Management LLC | 269 | 0.0% | 13F |
Insiders
- Aghazadeh BehzadDirector
- Doudna Jennifer A10% Owner
- GORDON CARL LDirector
- AH Bio Fund II, L.P.10% Owner
- ORBIMED ADVISORS LLCDirector
- Oakes Benjamin L.President, CEO
- Parrot DavidChief Financial Officer
- Watson James DeanDirector
- Lucas SvetlanaChief Business Officer
- Bleharski JoshuaDirector
Top institutional holders
based on 18.93M shares outstanding
US30d Avg
504.72K
60d Avg
436.22K
90d Avg
364.76K